ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-GPC3 Antibody-drug Conjugate ABBV-324

Its studies are mostly in Liver Neoplasms, led by AbbVie.

Furthest: phase 1, since Feb 28, 20251 company-led study, 1 open or runningNext primary completion: Sep 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 1since Feb 28, 2025Feb 28, 2025Sep 2030phase 1 · NCT06858813
  • Named in AbbVie’s own pipeline as ABBV-324, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2025First study: phase 1 study in Liver NeoplasmsFirst studyNCT06858813 · 232 planned · United States, China, Israel and more

Ahead

  1. Sep 2030Primary completion: phase 1 study in Liver NeoplasmsNCT06858813

TargetBeta

“Anti-GPC3 Antibody-drug Conjugate ABBV-324”name, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting the tumor-associated antigen glypican 3 (GPC3; GPC-3) ”NCIt, by rule

Other programs on GPC3

ProgramCompanyFurthest phaseStudies
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 33
codrituzumabHoffmann-La Rochephase 23
GPC3-targeted Plasmid DNA Vaccine NWRD06ruleNewish Biotech (Wuxi)phase 22
Actinium Ac 225 GPC3-targeted Peptide RYZ801Bristol-Myers Squibbphase 21
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 21
Anti-GPC3 Antibody-drug Conjugate ZW251ruleZymeworksphase 11
Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926ruleBayerphase 11
ACE723ruleacepodia-biotech-incphase 11
TQB6426ruleSino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06858813Liver Neoplasms · United States, China, Israel and more1RecruitingSep 2030232

How it is read

Names in the registry

  • “ABBV-324”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.